Search Result
Results for "
antidepressant-like effects
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N6947
-
Lutein
4 Publications Verification
Xanthophyll
|
Endogenous Metabolite
Apoptosis
Reactive Oxygen Species (ROS)
|
Neurological Disease
Inflammation/Immunology
|
|
Lutein (Xanthophyll) is a carotenoid with reported anti-inflammatory properties. A large body of evidence shows that lutein has several beneficial effects, especially on eye health . Lutein exerts its biological activities, including anti-inflammation, anti-oxidase and anti-apoptosis, through effects on reactive oxygen species (ROS) . Lutein is able to arrive in the brain and shows antidepressant-like and neuroprotective effects. Lutein is orally active .
|
-
-
- HY-N0571
-
-
-
- HY-N0765
-
-
-
- HY-10864
-
URB-597
5 Publications Verification
KDS-4103
|
FAAH
Autophagy
Mitophagy
|
Neurological Disease
|
|
URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
|
-
-
- HY-Y0511
-
|
Dimethylglycine; DMG; N-Methylsarcosine
|
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects .
|
-
-
- HY-14609
-
|
|
mGluR
|
Neurological Disease
|
|
MPEP Hydrochloride is a potent, selective, noncompetitive, orally active and systemically active mGlu5 receptor antagonist, with an IC50 of 36 nM for completely inhibiting quisqualate-stimulated phosphoinositide (PI) hydrolysis. MPEP Hydrochloride has anxiolytic-or antidepressant-like effects . MPEP (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-D0004
-
|
Azure B chloride
|
Monoamine Oxidase
|
Neurological Disease
|
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
-
-
- HY-15527
-
|
AC-5216; XBD-173
|
TSPO
|
Neurological Disease
Metabolic Disease
|
|
Emapunil (AC-5216), an orally active and selective TSPO (a mitochondrial benzodiazepine receptor) ligand, produces anti-anxiety and antidepressant-like effects in various animal models .
|
-
-
- HY-14609A
-
MPEP
Maximum Cited Publications
8 Publications Verification
|
mGluR
|
Neurological Disease
|
|
MPEP is a potent, selective, noncompetitive, orally active and systemically active mGlu5 receptor antagonist, with an IC50 of 36 nM for completely inhibiting quisqualate-stimulated phosphoinositide (PI) hydrolysis. MPEP has anxiolytic-or antidepressant-like effects . MPEP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-101202
-
|
NIH 10815
|
Opioid Receptor
|
Neurological Disease
|
|
SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
|
-
-
- HY-W001158S
-
|
Dimethylglycine-d6 hydrochloride; DMG-d6 hydrochloride; N-Methylsarcosine-d6 hydrochloride
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine-d6 (Dimethylglycine-d6) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
-
- HY-107729
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Lu AA33810 is a selective, orally active and brain-penetrant antagonist of neuropeptide Y5 receptor with a Ki of 1.5 nM for the rat receptor. Lu AA33810 exhibts antianxiolytic-like and antidepressant-like effects .
|
-
-
- HY-15446
-
|
RG7090; RO4917523
|
mGluR
|
Neurological Disease
|
|
Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [ 3H]-ABP688 (HY-110141)) and 35.6 nM (against [ 3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc .
|
-
-
- HY-W677042
-
|
5α-Androst-16-en-3α-ol
|
GABA Receptor
|
Neurological Disease
|
|
α-Androstenol (5α-Androst-16-en-3α-ol) is a steroid pheromone that has been found in boar testes and male axillary sweat. α-Androstenol is also a positive allosteric modulator of GABAA receptors, which enhances GABA-activated currents in primary mouse cerebellar granule cells (EC50 of 0.4 μM). α-Androstenol produces anxiolytic-like, antidepressant-like, and anticonvulsant effects in mice. α-Androstenol can be used for the research of seizures .
|
-
-
- HY-103151
-
|
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
|
CP94253 hydrochloride is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 hydrochloride induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 hydrochloride can be used for the research of depression and heightened aggressive behavior .
|
-
-
- HY-N6076
-
|
|
ERK
|
Neurological Disease
|
|
Tenuifoliside A is isolated from Polygala tenuifolia, has anti-apoptotic and antidepressant-like effects. Tenuifoliside A exhibits its neneurotrophic effects and promotes cell proliferation through the ERK/CREB/BDNF signal pathway in C6 cells .
|
-
-
- HY-14551
-
|
SR142801
|
Neurokinin Receptor
|
Neurological Disease
|
|
Osanetant (SR142801) is a selective NK3 receptor antagonist. Osanetant produces anxiolytic- and antidepressant-like effects and is researched for schizophrenia .
|
-
-
- HY-107741
-
-
-
- HY-123499
-
|
|
Somatostatin Receptor
|
Cardiovascular Disease
|
|
SRA880 is a non-peptide and selective somatostatin sst(1) receptor antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .
|
-
-
- HY-139048
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
-
- HY-W001158
-
|
Dimethylglycine hydrochloride; DMG hydrochloride; N-Methylsarcosine hydrochloride
|
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
-
- HY-110135A
-
|
|
IGF-1R
|
Neurological Disease
|
|
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects .
|
-
-
- HY-100936
-
|
SQ 20009; EHT 0202 hydrochloride
|
Phosphodiesterase (PDE)
GABA Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .
|
-
-
- HY-15691
-
|
|
Opioid Receptor
mTOR
|
Neurological Disease
Metabolic Disease
|
|
PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
|
-
-
- HY-117977
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
Inflammation/Immunology
|
|
FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, PDE4B1 and PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects .
|
-
-
- HY-Y0511R
-
|
Dimethylglycine (Standard); DMG (Standard); N-Methylsarcosine (Standard)
|
Reference Standards
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine (Dimethylglycine) (Standard) is the analytical standard of N,N-Dimethylglycine (HY-Y0511). This product is intended for research and analytical applications. N,N-Dimethylglycine (Dimethylglycine), a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine has antidepressant-like and surfactant effects.
|
-
-
- HY-18332C
-
|
|
Serotonin Transporter
Dopamine Transporter
|
Neurological Disease
|
|
DOV-216,303 (Free Base) is a potent triple serotonin, norepinephrine, and dopamine reuptake inhibitor, with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. Has antidepressant-like effects and increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats .
|
-
-
- HY-15401
-
|
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
|
WAY 163909 is an orally active, blood-brain barrier permeable 5-HT2C receptor-selective agonist. WAY 163909 exhibits an EC50 of 8 nM and a Ki of 10.5 nM for h5-HT2C. Instead of triggering apoptosis, WAY 163909 induces anorectic, antipsychotic-like, antidepressant-like, anti-aggressive and anti-compulsive effects. WAY 163909 alleviates ketamine-induced hypothermia, but impairs sexual function at high doses. With rapid antidepressant-like properties, WAY 163909 can be used in research related to obesity, schizophrenia, depression, obsessive-compulsive disorder, and anesthesia-induced hypothermia .
|
-
-
- HY-N0571R
-
-
-
- HY-101100
-
|
D-16949 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Anpirtoline (D-16949) hydrochloride is a centrally acting 5-HT1B receptor agonist, with Kis of 28 nM (5-HT1B), 150 nM (5-HT1A) and 1.49 μM (5-HT2). Anpirtoline hydrochloride has serotonergic, antinociceptive, antidepressant-like effects .
|
-
-
- HY-P10405A
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .
|
-
-
- HY-14551B
-
|
(S)-SR142801
|
Neurotensin Receptor
|
Neurological Disease
|
|
(S)-Osanetant is the S-enantiomer of Osanetant. Osanetant (SR142801) is a selective NK3 receptor antagonist. Osanetant produces anxiolytic- and antidepressant-like effects and is researched for schizophrenia .
|
-
-
- HY-N3204
-
|
|
Apoptosis
|
Neurological Disease
|
|
Neoechinulin A is an isoprenyl indole alkaloid that exhibits scavenging, neurotrophic factor-like, and anti-apoptotic activities. Neoechinulin A induces memory improvements and antidepressant-like effects in mice .
|
-
-
- HY-107751
-
-
-
- HY-14551C
-
|
SR142801 monohydrochloride
|
Neurokinin Receptor
|
Neurological Disease
|
|
Osanetant (SR142801) monohydrochloride is a selective NK3 receptor antagonist. Osanetant monohydrochloride produces anxiolytic- and antidepressant-like effects .
|
-
-
- HY-132993
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
|
Hcyb1 is a highly selective, orally active PDE2 inhibitor. Hcyb1 has a highly selective inhibition of PDE2A (IC50=0.57 μM) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 produces neuroprotective and antidepressant‐like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling .
|
-
-
- HY-10864R
-
|
KDS-4103 (Standard)
|
FAAH
Autophagy
Mitophagy
Reference Standards
|
Neurological Disease
|
|
URB-597 (Standard) is the analytical standard of URB-597. This product is intended for research and analytical applications. URB-597 (KDS-4103) is an orally bioavailable and selective FAAH inhibitor. URB-597 inhibits FAAH activity with an IC50s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity .
|
-
-
- HY-18332B
-
|
|
Dopamine Transporter
Adrenergic Receptor
5-HT Receptor
|
Neurological Disease
|
|
DOV-102,677 is an orally sctive triple monoamine neurotransmitter reuptake inhibitor that simultaneously inhibits the dopamine (DAT) (IC50 = 129 nM; Ki = 222 nM), norepinephrine (NET) (IC50 = 103 nM; Ki = 1030 nM), and serotonin (SERT) (IC50 = 133 nM; Ki = 740 nM) transporters. DOV-102,677 demonstrated significant antidepressant-like activity and sensory-motor gating regulatory effects in mouse experiments. DOV-102,677 can be used for research on depression .
|
-
-
- HY-D0004R
-
|
Azure B chloride (Standard)
|
Reference Standards
Monoamine Oxidase
|
Neurological Disease
|
|
Azure B (Standard) is the analytical standard of Azure B. This product is intended for research and analytical applications. Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
-
-
- HY-P10405
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .
|
-
-
- HY-107479
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
(R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects .
|
-
-
- HY-139806
-
|
|
Somatostatin Receptor
|
Others
|
|
SRA880 (free base) is a compound with antidepressant-modulating effects. It is a somatostatin-1 autoreceptor antagonist that can synergize with imipramine to produce antidepressant-like effects and affect BDNF mRNA expression and phosphorylation of related proteins.
|
-
-
- HY-105058A
-
|
14α/β-RU 24722
|
Drug Derivative
|
Neurological Disease
|
|
14α/β-Vindeburnol (14α/β-RU 24722) a synthetic molecule derived from the eburnamine-vincamine alkaloid group, has many neuropsychopharmacological and antidepressant-like effects .
|
-
-
- HY-108481
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
L-760735 is a high affinity, selective and orally active NK1 receptor antagonist with an IC50 of 0.19 nM for human NK1 receptors. L-760735 exhibits anxiolytic and antidepressant-like effects .
|
-
-
- HY-176436S
-
-
-
- HY-10049A
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
CP 122721 hydrochloride is a potent, non-peptide and selective nonpeptide neurokinin NK1 antagonist, with a pIC50 of 9.8 for human NK1 receptor expressed in IM-9 cells. CP 122721 hydrochloride exhibits anxiolytic and antidepressant-like effects .
|
-
-
- HY-15527R
-
|
AC-5216 (Standard); XBD-173 (Standard)
|
Reference Standards
TSPO
|
Neurological Disease
Metabolic Disease
|
|
Emapunil (Standard) is the analytical standard of Emapunil. This product is intended for research and analytical applications. Emapunil (AC-5216), an orally active and selective TSPO (a mitochondrial benzodiazepine receptor) ligand, produces anti-anxiety and antidepressant-like effects in various animal models .
|
-
-
- HY-139048A
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
-
- HY-N0765R
-
|
|
Reference Standards
Fungal
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Isoliquiritin (Standard) is the analytical standard of Isoliquiritin. This product is intended for research and analytical applications. Isoliquiritin, isolated from Licorice Root, inhibits angiogenesis and tube formation. Isoliquiritin also exhibits antidepressant-like, anti-oxidative, anti-Inflammatory effects and antifungal activity .
|
-
-
- HY-121704
-
|
|
iGluR
|
Neurological Disease
|
|
SR 57227A Free base is a highly selective compound for both peripheral and central 5-HT3 receptors and acts as an inhibitor of NMDA receptor-mediated responses in rat cortical pyramidal cells, demonstrating antidepressant-like effects in rats while reducing isolation-induced aggressive behavior.
|
-
- HY-15401A
-
|
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
|
WAY 163909 hydrochloride is an orally active, blood-brain barrier permeable 5-HT2C receptor-selective agonist. WAY 163909 hydrochloride exhibits an EC50 of 8 nM and a Ki of 10.5 nM for h5-HT2C. Instead of triggering apoptosis, WAY 163909 hydrochloride induces anorectic, antipsychotic-like, antidepressant-like, anti-aggressive and anti-compulsive effects. WAY 163909 hydrochloride alleviates ketamine-induced hypothermia, but impairs sexual function at high doses. With rapid antidepressant-like properties, WAY 163909 hydrochloride can be used in research related to obesity, schizophrenia, depression, obsessive-compulsive disorder, and anesthesia-induced hypothermia .
|
-
- HY-W728451
-
|
|
FAAH
|
Cardiovascular Disease
Neurological Disease
|
|
URB694 is a carbamate FAAH inhibitor that irreversibly carbamoylate the nucleophile catalytic serine in FAAH active site. URB694 exhibits antidepressant-like activity and cardioprotective effects. URB694 can be used to prepare 11C-Carbonyl-URB694 for in vivo positron emission tomography (PET) imaging studies of the brain FAAH .
|
-
- HY-170898
-
|
|
iGluR
|
Neurological Disease
|
|
Antidepressant agent 8 (Compound 1f) is a selective antagonist for the NMDA receptor GluN1/2A with an IC50 of 2.94 μmol/L. Antidepressant agent 8 exhibits antidepressant-like effects in Hydrocortisone (HY-N0583)-induced zebrafish depression model. Antidepressant agent 8 can cross blood-brain barrier .
|
-
- HY-175508
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 9 is an orally active NMDA receptor positive allosteric modulator (PAM). NMDA receptor modulator 9 enhances GluN2A receptor activity. NMDA receptor modulator 9 demonstrates significant antidepressant-like effects in chronic restraint stress (CRS)-induced depression mice. NMDA receptor modulator 9 can be used for the study of depression .
|
-
- HY-101100A
-
|
D-16949
|
5-HT Receptor
|
Neurological Disease
|
|
Anpirtoline (D-16949) is a centrally acting 5-HT1B receptor agonist, with Kis of 28 nM (5-HT1B), 150 nM (5-HT1A) and 1.49 μM (5-HT2). Anpirtoline has serotonergic, antinociceptive, antidepressant-like effects .
|
-
- HY-103151A
-
|
|
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
|
CP94253 is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 can be used for the research of depression and heightened aggressive behavior .
|
-
- HY-101202A
-
|
(Rac)-NIH 10815
|
Opioid Receptor
|
Neurological Disease
|
|
(Rac)-SNC80 is a racemate of SNC80 (HY-101202). SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
|
-
- HY-15691A
-
|
|
Opioid Receptor
mTOR
|
Neurological Disease
Metabolic Disease
|
|
PF-4455242 hydrochloride is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-4455242 hydrochloride blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-4455242 hydrochloride promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-4455242 hydrochloride attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-4455242 hydrochloride can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
|
-
- HY-W001158S1
-
|
Dimethylglycine-d3 hydrochloride; DMG-d3 hydrochloride; N-Methylsarcosine-d3 hydrochloride
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine-d3 (Dimethylglycine-d3) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
- HY-100936R
-
|
SQ 20009 (Standard); EHT 0202 hydrochloride (Standard)
|
Reference Standards
Phosphodiesterase (PDE)
GABA Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Etazolate (hydrochloride) (Standard) is the analytical standard of Etazolate (hydrochloride). This product is intended for research and analytical applications. Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .
|
-
- HY-149536
-
|
|
Potassium Channel
|
Neurological Disease
|
|
TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .
|
-
- HY-149538
-
|
|
Potassium Channel
|
Neurological Disease
|
|
TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
|
-
- HY-N2439R
-
|
|
Reference Standards
Others
|
Neurological Disease
|
|
Methyl isoeugenol (Standard) is the analytical standard of Methyl isoeugenol. This product is intended for research and analytical applications. Methyl isoeugenol (MIE) is a natural food flavour that can be isolated from Pimenta pseudocaryophyllus leaf. Methyl isoeugenol shows anxiolytic and antidepressant like effects. Methyl isoeugenol is orally active .
|
-
- HY-128743R
-
|
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Methyl isoeugenol (Standard) is the analytical standard of Methyl isoeugenol. This product is intended for research and analytical applications. Methyl isoeugenol (MIE) is a natural food flavour that can be isolated from Pimenta pseudocaryophyllus leaf. Methyl isoeugenol shows anxiolytic and antidepressant like effects. Methyl isoeugenol is orally active .
|
-
- HY-180212A
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
SYK-1106 dihydrochloride is a selective δ opioid receptor (DOR) agonist with an EC50 of 0.089 nM. SYK-1106 dihydrochloride shows high selectivity over MOR and KOR. SYK-1106 dihydrochloride exhibits antidepressant-like effects in the mouse forced-swimming tests. SYK-1106 dihydrochloride can be used for the research of depression .
|
-
- HY-182363
-
|
|
Serotonin Transporter
|
Neurological Disease
|
|
A6CDQ is a human organic cation transporter (hOCT) inhibitor with antidepressant-like activity that can cross the blood-brain barrier. A6CDQ potently inhibits the transport activities mediated by hOCT1, hOCT2 and hOCT3. A6CDQ exhibits significant antidepressant-like effects in the mouse tail suspension test. A6CDQ can be used in studies related to depression .
|
-
- HY-10347
-
|
S-20499
|
5-HT Receptor
|
Neurological Disease
|
|
Alnespirone (S-20499) is a selective, orally active 5-HT1A receptor agonist (K0.5 = 0.2 nM). Alnespirone shows antidepressant-like and anxiolytic effects .
|
-
- HY-180212
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
SYK-1106 is a potent delta-opioid receptor (DOR) agonist with an EC50 of 89 pM and a Ki of 848 pM. SYK-1106 is selective for μ and κ opioid receptors, with Ki values of 9.54 nM and 2.45 nM, respectively. SYK-1106 induces dose-dependent antidepressant-like effects. SYK-1106 can be used for the research of depression .
|
-
- HY-186170
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
R-MDMA, 4-methylenedioxymethamphetamine (MDMA) isomer, is a 5-HT2A/5-HT2C receptor antagonist with an IC50 of 629 and 61.4 nM. R-MDMA promotes cortical neuron growth. R-MDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDMA can be used for the researches of post-traumatic stress disorder and depression .
|
-
- HY-14609R
-
|
|
mGluR
|
Neurological Disease
|
|
MPEP (Hydrochloride) (Standard) is the analytical standard of MPEP (Hydrochloride). This product is intended for research and analytical applications. MPEP Hydrochloride is a potent, selective, noncompetitive, orally active and systemically active mGlu5 receptor antagonist, with an IC50 of 36 nM for completely inhibiting quisqualate-stimulated phosphoinositide (PI) hydrolysis. MPEP Hydrochloride has anxiolytic-or antidepressant-like effects . MPEP (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-183101
-
|
|
iGluR
NADPH Oxidase
|
Neurological Disease
|
|
AMPAR modulator-12 is a blood-brain barrier-permeable AMPAR positive allosteric modulator. AMPAR modulator-12 reduces NOX-1 expression, enhances AMPAR-mediated currents, promotes excitatory postsynaptic transmission and restores AMPAR function. AMPAR modulator-12 enhances excitatory and inhibitory synaptic transmission, reduces burst firing in the lateral habenula after withdrawal, and produces rapid and sustained antidepressant-like effects. AMPAR modulator-12 is applicable for the research of depression .
|
-
- HY-B2185
-
|
|
Dopamine Receptor
Potassium Channel
AMPK
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Tipepidine citrate is a non-narcotic antitussive agent. Tipepidine citrate reversibly inhibits dopamine D2 receptor-mediated GIRK current (IDA(GIRK)), thereby activating VTA dopamine neurons, with an IC50 of 7.0 μM for IDA(GIRK). Tipepidine activates AMPK. Tipepidine citrate has antidepressant-like effects. Tipepidine citrate enhances the analgesic effect of Carbamazepine (HY-B0246). Tipepidine citrate improves adipose tissue fibrosis and glucose intolerance in high-fat diet-induced obese mice .
|
-
- HY-103151R
-
|
|
Reference Standards
5-HT Receptor
|
Neurological Disease
Metabolic Disease
|
|
CP94253 hydrochloride (Standard) is the analytical standard of CP94253 hydrochloride (HY-103151). This product is intended for research and analytical applications. CP94253 hydrochloride is an orally active, brain-penetrant and selective 5-HT1B receptor agonist with an Ki of 2 nM. CP94253 hydrochloride induces antidepressant-like effects, waking enhancement, sleep inhibition, increased sleep latency, hyperlocomotion, and suppressed aggressive behavior. CP94253 hydrochloride can be used for the research of depression and heightened aggressive behavior .
|
-
- HY-101202R
-
|
NIH 10815 (Standard)
|
Opioid Receptor
Reference Standards
|
Neurological Disease
|
|
SNC80 (Standard) is the analytical standard of SNC80 (HY-101202). This product is intended for research and analytical applications. SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
|
-
- HY-179568
-
|
|
Monoamine Transporter
|
Neurological Disease
|
|
F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC50 = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions .
|
-
- HY-182601
-
|
|
EAAT
Interleukin Related
|
Neurological Disease
|
|
MC-100093 is an orally active, blood-brain barrier-permeable GLT-1 expression upregulator . MC-100093 upregulates the expression of GLT-1 and xCT in rats, and alleviates fentanyl-induced GLT-1 downregulation, IL-6 upregulation and motor hyperactivity. MC-100093 upregulates GLT-1 expression and enhances glutamate uptake in astrocyte-neuron co-culture systems. MC-100093 reduces ethanol consumption and preference, and exerts gender-specific antidepressant-like effects . MC-100093 can be used in studies related to fentanyl overdose, mood disorders and alcohol use disorders .
|
-
- HY-114515
-
|
RG7090 sulfate; RO4917523 sulfate
|
mGluR
|
Neurological Disease
|
|
Basimglurant (RG7090; RO4917523) sulfate is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [ 3H]-ABP688 (HY-110141)) and 35.6 nM (against [ 3H]-MPEP (HY-14609A)). Basimglurant sulfate inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant sulfate can be used in research on depression, fragile X syndrome, anxiety disorders, etc .
|
-
- HY-186169
-
|
|
5-HT Receptor
Drug Derivative
|
Neurological Disease
|
|
R-MDDMA, 4-methylenedioxymethamphetamine (MDMA) analogue, is a 5-HT2A/5-HT2C receptor modulator. R-MDDMA shows antagonistic activity against 5-HT2A/5-HT2C with IC50 values of 642 and 137 nM, and also shows partial agonist activity with EC50 values of 24.5 and 14.4 nM, but does not activate 5-HT2B receptors. R-MDDMA promotes cortical neuron growth. R-MDDMA facilitates fear extinction learning and produces antidepressant-like effects in preclinical rodent models. R-MDDMA can be used for the researches of post-traumatic stress disorder and depression .
|
-
- HY-15446R
-
|
RG7090 (Standard); RO4917523 (Standard)
|
Reference Standards
mGluR
|
Neurological Disease
|
|
Basimglurant (RG7090; RO4917523) (Standard) is the analytical standard of Basimglurant. This product is intended for research and analytical applications. Basimglurant is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [ 3H]-ABP688 (HY-110141)) and 35.6 nM (against [ 3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc.
|
-
- HY-179579
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
TMU4142 is a selective 5-HT1a agonist with high GoA activity. TMU4142 has weak Gi3 activity, can elicit rapid antidepressant like effects without triggering significant activation of dorsal raphe nucleus (DRN) 5-HT1a R autoreceptors or serotonergic neuron firing. TMU4142 demonstrates fast-acting efficacy in mouse models of depression. TMU4142 can be used for antidepressants research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0004
-
|
Azure B chloride
|
Fluorescent Dyes
|
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
-
- HY-D0004R
-
|
Azure B chloride (Standard)
|
Fluorescent Dyes
|
|
Azure B (Standard) is the analytical standard of Azure B. This product is intended for research and analytical applications. Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
| Cat. No. |
Product Name |
Type |
-
- HY-15401A
-
|
|
Biochemical Assay Reagents
|
|
WAY 163909 hydrochloride is an orally active, blood-brain barrier permeable 5-HT2C receptor-selective agonist. WAY 163909 hydrochloride exhibits an EC50 of 8 nM and a Ki of 10.5 nM for h5-HT2C. Instead of triggering apoptosis, WAY 163909 hydrochloride induces anorectic, antipsychotic-like, antidepressant-like, anti-aggressive and anti-compulsive effects. WAY 163909 hydrochloride alleviates ketamine-induced hypothermia, but impairs sexual function at high doses. With rapid antidepressant-like properties, WAY 163909 hydrochloride can be used in research related to obesity, schizophrenia, depression, obsessive-compulsive disorder, and anesthesia-induced hypothermia .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W001158
-
|
Dimethylglycine hydrochloride; DMG hydrochloride; N-Methylsarcosine hydrochloride
|
Endogenous Metabolite
iGluR
Amino Acid Derivatives
|
Neurological Disease
Metabolic Disease
|
|
N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
- HY-P10405A
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
TAT-D1 peptide acetate is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .
|
-
- HY-P10405
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W001158S
-
|
|
|
N,N-Dimethylglycine-d6 (Dimethylglycine-d6) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
-
- HY-176436S
-
|
|
|
GW-117 is a 5-HT2C receptor antagonist and a melatonin (MT1/MT2) receptor agonist. GW-117 shows antidepressant-like and anxiolytic-like effects .
|
-
-
- HY-W001158S1
-
|
|
|
N,N-Dimethylglycine-d3 (Dimethylglycine-d3) hydrochloride is the deuterium labeled N,N-Dimethylglycine hydrochloride (HY-W001158). N,N-Dimethylglycine (Dimethylglycine) hydrochloride, a natural N-methylated glycine, is a nutrient supplement and acts as an NMDAR glycine site partial agonist. N,N-Dimethylglycine hydrochloride is a methyl donor that can improve immunity, act as an antioxidant to prevent oxidative stress, and scavenge excess free radicals. N,N-Dimethylglycine hydrochloride has antidepressant-like and surfactant effects .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: